-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 OnJc8FUX5sRqkpLu5DLrbp2Dyqol6PWa6LVoB9uwDoWk3M5FLdUF+ODbcobLrCZe
 Z5J3VWUDOgkEkEPKhb2w7A==

<SEC-DOCUMENT>0000950144-07-007015.txt : 20070731
<SEC-HEADER>0000950144-07-007015.hdr.sgml : 20070731
<ACCEPTANCE-DATETIME>20070731150456
ACCESSION NUMBER:		0000950144-07-007015
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070725
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070731
DATE AS OF CHANGE:		20070731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER & OFFICE EQUIPMENT [3570]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		071012488

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g08657e8vk.htm
<DESCRIPTION>GEOVAX LABS, INC.
<TEXT>
<HTML>
<HEAD>
<TITLE>GEOVAX LABS, INC.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): July&nbsp;25, 2007</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in Charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Illinois<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1256 Briarcliff Road N.E.<BR>
Emtech Bio Suite&nbsp;500<BR>
Atlanta, Georgia 30306<BR>
(Address of Principal Executive Offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(404)&nbsp;727-0971<BR>
(Issuer Telephone number)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4<SUP style="font-size: 85%; vertical-align: text-top">&#169;</SUP> under the Exchange Act (17 CFR
240.13(e)-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.01 Entry into a Material Definitive Agreement.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">See the discussion under Item&nbsp;3.02, below, which is incorporated herein by reference.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;3.02 Unregistered Sales of Equity Securities</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Subscription Agreement and Warrants</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On July&nbsp;25, 2007, GeoVax Labs, Inc. (&#147;GeoVax&#148;) entered into a binding agreement with an
institutional investor (the &#147;Investor&#148;), pursuant to which it agreed, subject to certain customary
closing conditions, to sell to the Investor 48,387,097 shares of its common stock for a price of
$0.155 per share, or an aggregate of $7,500,000. A definitive Subscription Agreement with the
Investor was signed on July&nbsp;30, 2007. The closing under the Subscription Agreement is expected to
occur on or about August&nbsp;6, 2007 as to 22,580,645 shares, or $3,500,000 (the &#147;First Closing&#148;); and
on or about November&nbsp;5, 2007 as to 25,806,452 shares, or $4,000,000 (the &#147;Second Closing&#148;). The
shares to be sold by GeoVax constitute approximately 6.8% of the number of shares of its common
stock outstanding on July&nbsp;31, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the Subscription Agreement, at the First Closing GeoVax will issue to the Investor a
stock purchase warrant to purchase 18,333,333 shares of its common stock at a price of $0.33 per
share, and at the Second Closing GeoVax will issue to the Investor a stock purchase warrant to
purchase 16,666,667 shares of its common stock at a price per share based on the closing market
price of GeoVax&#146;s common stock as of the date immediately preceding the Second Closing. Both of
the stock purchase warrants will be exercisable for a period of three years from the date of
issuance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Registration Rights</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Under the Subscription Agreement, GeoVax granted the Investor &#147;piggyback&#148; registration rights as to
the shares to be issued pursuant to the Subscription Agreement and as to the shares issuable upon
exercise of the related warrants. The Investors shall have the right to register such shares under
the Securities Act in connection with future underwritten public offerings of shares of GeoVax
common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Other</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The offer and sale of the shares will not be registered under the Securities Act in reliance upon
the exemption from registration contained in Section&nbsp;4(2) of the Securities Act and Regulation&nbsp;D
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">promulgated thereunder. The shares sold by GeoVax may not be reoffered or sold in the United States
by the holders in the absence of an effective registration statement, or exemption from the
registration requirements, under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A copy of the definitive form of the Subscription Agreement relating to the sale of the shares is
filed as Exhibit&nbsp;10.1 to this report. The summary of matters set forth above is qualified by
reference to such exhibit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On July&nbsp;31, 2007, GeoVax issued a press release announcing the signing of the Subscription
Agreement. A copy of the press release is filed as Exhibit&nbsp;99.1 to this report and incorporated
herein by reference.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following exhibit is filed with this Current Report:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">10.1 Subscription Agreement
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">99.1 Press Release
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly
authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: July&nbsp;31, 2007
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>g08657exv10w1.htm
<DESCRIPTION>EX-10.1 SUBSCRIPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-10.1 SUBSCRIPTION AGREEMENT</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;10.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUBSCRIPTION AGREEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned (&#147;Subscriber&#148;), hereby subscribes for and agrees to purchase and pay for an
aggregate of (a)&nbsp;48,387,097 shares<SUP style="font-size: 85%; vertical-align: text-top">1</SUP> (the &#147;Shares&#148;) of the common stock, par value $0.001
per share (the &#147;Common Stock&#148;), of GeoVax Labs, Inc., an Illinois Corporation (&#147;GeoVax&#148;), and (b)
common stock purchase warrants (the &#147;Warrants&#148;) to purchase an aggregate of 35,000,000 shares (the
&#147;Warrant Shares&#148;) of the Common Stock, for aggregate consideration of SEVEN MILLION FIVE HUNDRED
FIFTY THOUSAND DOLLARS ($7,500,000.00) (the &#147;Aggregate Purchase Price&#148;), on the terms and
conditions set forth herein. The Shares, the Warrants and the Warrant Shares are sometimes
collectively referred to herein as the &#147;Securities.&#148;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A. Subscriber shall purchase on the following dates such number of the Shares and Warrants to
purchase such number of the Warrant Shares subscribed for hereunder for such portion of the
Aggregate Purchase Price as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On August&nbsp;6, 2007 (the &#147;First Closing Date&#148;), (a)&nbsp;22,580,645 of the Shares and
(b)&nbsp;a Warrant to purchase 18,333,333 Warrant Shares pursuant to the form of Warrant
attached hereto as <U>Exhibit&nbsp;A</U>, for THREE MILLION FIVE HUNDRED FIFTY THOUSAND
DOLLARS ($3,500,000.00); and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On November&nbsp;3, 2007 (the &#147;Second Closing Date&#148;), (a)&nbsp;25,806,452 of the Shares
and (b)&nbsp;a Warrant to purchase 16,666,667 Warrant Shares pursuant to the form of Warrant
attached hereto as <U>Exhibit&nbsp;B</U>, for FOUR MILLION DOLLARS ($4,000,000.00).</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All payments hereunder shall be made by wire transfer of immediately available funds pursuant
to GeoVax&#146;s wire transfer instructions.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">B. In order to induce GeoVax to accept this subscription, and in order to determine whether
Subscriber is qualified to acquire the Securities pursuant to an exemption from the registration
requirements of the Securities Act of 1933, as amended (&#147;Act&#148;), provided by Section&nbsp;4(2) of the Act
or Regulation&nbsp;D promulgated thereunder, and pursuant to any other applicable laws regulating the
offer and sale of securities in the state or states in the United States in which Subscriber is
domiciled, Subscriber hereby represents, warrants and certifies that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber has been fully informed to its complete satisfaction concerning the
organization aspects, business, limited current operations, finances, and all other
matters relating to GeoVax which it consider significant for the purpose of making an
investment decision with respect to the Securities. In particular, Subscriber has
examined GeoVax&#146;s most recent annual report on Form 10-K and its most recent quarterly
filings on Form 10-Q. Subscriber has been offered the opportunity to discuss GeoVax and
its affairs with members of GeoVax&#146;s management, to review such documents and records
as it considers appropriate, and has received all</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 18%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top">1</SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Based upon a per share purchase price equal
to the lesser of (a) $0.155 per share and (b)&nbsp;70% of the closing market price
per share on August&nbsp;6, 2007.</TD>
</TR>

</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>information, which it has requested with respect to GeoVax. Subscriber is aware of
the present concentrated stock holdings of GeoVax.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is fully aware of all of the risks involved in purchasing the
Securities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is aware that there will be limited liquidity in an investment in
GeoVax Securities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is aware that the Securities do not carry preemptive rights or
cumulative voting.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is aware that there can be no assurance that GeoVax will be
profitable in the future.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">6.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is also aware that GeoVax will be in need of additional funds in
order to attempt to fulfill its business plans and there is no assurance that it will
be able to obtain such funds.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">7.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber understands that there is only a limited market for GeoVax&#146;s
Securities and that there can be no assurance that an active market will develop in the
future.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">8.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber understands that the Securities have not been registered nor have
they been registered or qualified under the applicable securities laws of any state in
the United States, and are being issued in reliance upon the truth and accuracy of the
representations made herein with respect to Subscriber&#146;s investment intent and
suitability as an investor. Subscriber hereby certifies that it is purchasing the
Securities for investment for its own account, with no present intention of making any
sale, transfer or distribution of them. Subscriber understands that the Securities may
not be sold or transferred without registration under the Act, or qualification or
registration under the applicable state securities laws, unless there is an exemption
from such registration or qualification then available. Subscriber consents to having a
legend on the certificates representing the Securities to that effect. Subscriber is
aware that the Shares and the Warrant Shares will carry certain limited registration
rights.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">9.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is a sophisticated investor with substantial experience in
securities of speculative businesses. Subscriber is able to judge the suitability of
this investment for Subscriber and the risks involved, and understands that the
Securities will be unmarketable for an indefinite period of time, and that if GeoVax is
not successful, all or a substantial part of Subscriber&#146;s investment could be lost.
Subscriber further certifies that its net worth or annual income is such that the loss
of Subscriber&#146;s entire investment, or its unavailability, will not result in serious
financial harm or determent to Subscriber.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">10.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is aware that GeoVax may sell the Securities to Subscriber only if
Subscriber qualifies according to the express standards stated herein. If the
Securities are purchased in a fiduciary capacity, the person or persons for whom the
purchase is made meet the standards set forth herein and the representation and
warranties shall</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">be deemed to have been on behalf of the person or persons for whom Subscriber is so
purchasing. Subscriber represents and warrants that it meets the following investors
standards:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber and its representatives have been afforded access to such
information concerning GeoVax and about the proposed operations of GeoVax as
have been requested by Subscriber or them and that such materials were
sufficient to enable Subscriber to arrive at a reasoned investment decision with
respect to an investment in the Securities.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">11.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber meets one of the standards as an &#147;Accredited Investor&#148;, as
such term is defined in Rule 501(a) of Regulation&nbsp;D.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On the terms and subject to the conditions of this paragraph 12, Subscriber
shall have the limited right to register the Shares and the Warrant Shares as described
herein. For purposes of this discussion, the term &#147;Holders&#148; includes those shareholders
that have purchased shares of GeoVax Common Stock under a Subscription Agreement having
terms substantially identical to the terms of this Subscription Agreement.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>&#147;Piggyback&#148; Registration Rights</U>. Holders shall have the right
to register the Registrable Securities under the Act in connection with future
underwritten public offerings of shares of GeoVax Common Stock. The term
&#147;Registrable Securities&#148; means: (i)&nbsp;the Shares issued in connection with this
Subscription Agreement; (ii)&nbsp;the Warrant Shares underlying the Warrants issued
in connection with this Subscription Agreement; and (iii)&nbsp;any other securities
of GeoVax issued as (or issuable upon the conversion or exercise of any warrant,
right or other security which is issued as) a dividend or other distribution
with respect to, or in exchange for or in replacement of, such securities
referenced in (i)&nbsp;and (ii)&nbsp;immediately above, excluding in all cases, however,
any Registrable Securities sold in any public offering pursuant to a
registration or an exemption from registration.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>On the terms and subject to the conditions stated herein, each time GeoVax
shall determine to file a registration statement under the Act in connection
with the proposed offer and sale for money of any of its shares of Common
Stock in an underwritten public distribution by it (other than (i)&nbsp;a
registration statement relating solely to employee stock option or purchase
plans, or (ii)&nbsp;a registration statement on Form S-4 relating solely to Rule
145 under the Act), GeoVax shall give written notice of its determination to
Holders; provided, however, that GeoVax shall have no such obligation if the
managing underwriter of the subject proposed offering objects in a writing
addressed to GeoVax to the inclusion of any Registrable Securities in the
subject registration statement or offering.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Under Holders&#146; written request, which must have been received by GeoVax
within 20&nbsp;days after any such notice from GeoVax, GeoVax shall use its best
efforts to cause all such Registrable Securities of which Holders have
requested registration to be included in such registration statement and in
any</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">necessary registration, qualification or other filing under the applicable
state securities or blue sky laws, all to the extent required to permit the
sale or other disposition to be made of the Registrable Securities to be so
registered. In the event that the aggregate number of Registrable Securities
requested by the Holders to be registered in any underwritten public
distribution (the &#147;Piggyback Shares&#148;) exceeds twenty percent (20%) of the
aggregate number of shares of GeoVax Common Stock being registered in such
underwritten public distribution, then the aggregate number of the Piggyback
Shares to be registered and included in such public distribution shall be
reduced pro rata among the Holders of the Piggyback Shares to twenty percent
(20%) of the aggregate number of shares being registered in such underwritten
public distribution.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">All Holders proposing to distribute their Registrable Securities through an
underwriting pursuant to this paragraph 12 shall (together with GeoVax and
any other holders distributing their securities through such underwriting)
enter into an underwriting agreement in customary form with the underwriter
or underwriters selected for underwriting by GeoVax. If any Holder
disapproves of the terms of any such underwriting, he may elect to withdraw
therefrom by written notice to GeoVax and the underwriter. Any Registrable
Securities excluded or withdrawn from such underwriting shall not be
withdrawn from such registration except at the election of the Holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">Holders shall cooperate with GeoVax, execute any documents, instrument and
agreements, and take any further actions reasonably necessary to effect such
registrations, qualifications or other filings, and the public offering in
connection therewith shall be paid by GeoVax; provided, however, that Holders
of the Piggyback Shares participating in any such registration shall bear
their pro rata share of the underwriting fees, discounts and commissions.
Holders shall not sell or otherwise transfer any shares of GeoVax Common
Stock held by them which are not included in the underwritten public offering
for a period commencing on the date of the commencement of the public
offering, and ending on the earlier of the date of termination of the public
offering or 90&nbsp;days from the commencement of the public offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 8%">Notwithstanding any contrary provision of this paragraph 12, GeoVax shall not
be required to effect any registrations under the 1933 Act or under any state
securities laws on behalf of any Holder or Holders if, in the opinion of
counsel for GeoVax, the offering or transfer by such Holder or Holders in the
manner proposed (including, without limitation, the number of shares proposed
to be offered or transferred and the method of offering or transfer) is
exempt from the registration requirements of the 1933 Act and the securities
laws of applicable states.
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Termination of Piggyback Registration Rights</U>. The piggyback
registration rights under this paragraph 12 are not transferable or assignable
and shall terminate on the first anniversary of the date of the issuance of the
Registrable Securities to the undersigned Holder.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>Expenses of Registration</U>. All expenses incurred in connection
with any registration shall be borne by GeoVax; provided, however, GeoVax shall
not be required to pay any fees of Holders&#146; legal counsel or any underwriter
fees, discounts or commissions.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">12.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U>No Assurance of State Registration</U>. There can be no assurance
that the state in which a Holder resides will permit the registration of the
Registrable Securities within such state. Accordingly, even if the Shares and
Warrant Shares are subsequently registered under federal securities laws, of
which there can be no assurance, there can be no assurance that the Shares and
Warrant Shares can be registered under applicable sate law due to merit or other
requirements. Accordingly, there can be no assurance that a Holder will be able
to have its Shares and Warrant Shares registered in its state of domicile or
residence, as applicable. In such event, a Holder would continue to own
restricted securities under the state securities law.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber further represents and warrants that:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Considering all facts in Subscriber&#146;s financial circumstances
(including, but not limited to requirements for current income) Subscriber is
able to bear the economic risk of an investment in the Securities, including a
loss of its entire investment.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">13.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber is purchasing the Securities for its own account for
personal investment purposes only and with no view to or any present intention,
agreement or agreements for the distribution, transfer, assignment, resale,
subdivision or hypothecation thereof, and Subscriber understands that in any
event such Securities will be subject to restrictions against any such
transferability in the absence of registration under the Act.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">14.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subscriber has the full power and authority to execute and deliver this
Subscription Agreement and to perform its obligations hereunder and this Subscription
Agreement is a legally binding obligation of Subscriber in accordance with its terms.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">C. Subscriber&#146;s obligations hereunder are subject to the satisfaction (or waiver in Subscriber&#146;s
sole discretion) of the following conditions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax shall have established a financial public and investor relations budget
acceptable to Subscriber as per Item&nbsp;2 below.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax shall have engaged an investor relations consultant acceptable to
Subscriber for a period of not less than one year, and shall have agreed to retain
Financial Relations Board or another public relations firm mutually acceptable to
Subscriber and GeoVax. The total annual budget required by this provision for engaging
the aforemented consultant and public relations firm shall not exceed $240,000,.</TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">D<I>. </I>GeoVax&#146;s obligations hereunder are subject to it having a sufficient number of duly authorized
and unreserved shares of its Common Stock on the First Closing Date and the Second Closing Date for
issuance of the number of Shares and Warrant Shares underlying the Warrants to be issued hereunder
on each of such closing dates<I>.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: July&nbsp;30, 2007
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Very truly yours,<BR>
PURE Capital, LLC<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>

<TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Paul Benson
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Paul Benson&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Managing Partner&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Agreed to and Accepted:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="65%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Donald Hildebrand
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Donald Hildebrand, CEO
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U><B>EXHIBIT A</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF AUGUST 6, 2007 WARRANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><DIV style="width: 100%; border-bottom: 0px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;1933 ACT&#148;), OR UNDER APPLICABLE STATE SECURITIES LAWS. THE
WARRANT HAS BEEN TAKEN BY THE REGISTERED OWNER FOR INVESTMENT, AND WITHOUT A VIEW TO RESALE OR
DISTRIBUTION THEREOF, AND MAY NOT BE TRANSFERRED OR DISPOSED OF WITHOUT AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT SUCH TRANSFER OR DISPOSITION DOES NOT VIOLATE THE 1933 ACT, THE
RULES AND REGULATIONS THEREUNDER, OR APPLICABLE STATE SECURITIES LAWS. IN CONNECTION WITH
COMPLIANCE WITH THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS, NO TRANSFER OF THIS WARRANT OR
THE SECURITIES UNDERLYING THIS WARRANT SHALL BE MADE UNLESS THE CONDITIONS SPECIFIED HEREIN ARE
SATISFIED.
</DIV>

<DIV align="center" style="margin-top: 6pt">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top"><B>No. &#95;&#95;&#95;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>Shares: 18,333,333</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>COMMON STOCK PURCHASE WARRANT</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This is to certify that, for value received, <B>PURE Capital, LLC </B>(&#147;Holder&#148;) is entitled to
purchase, subject to the provisions of this Common Stock Purchase Warrant (&#147;Warrant&#148;), from GEOVAX
LABS, INC., a corporation duly organized and existing under the laws of the State of Illinois (the
&#147;Company&#148;), 18,333,333 shares of $0.001 par value per share common stock of the Company (&#147;Shares&#148;),
at a price of U.S. $0.33 per Share, during the period commencing August&nbsp;6, 2007, and terminating
on August&nbsp;5, 2010, at 5:00 P.M. New York Time. This Warrant is not redeemable by the Company. The
number of Shares to be received upon the exercise of this Warrant and the price to be paid for a
Share may be adjusted from time to time as hereinafter set forth. The exercise price of a Share in
effect at any time and as adjusted from time to time is hereinafter sometimes referred to as
&#147;Exercise Price.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(A)&nbsp;EXERCISE OF WARRANT. Subject to the provisions of Section (G)&nbsp;hereof, this Warrant may be
exercised in whole or in part at any time or from time to time on or after August
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">6, 2007 and until August&nbsp;5, 2010, or, if either such day is a day on which banking institutions are
authorized by law to close, then on the next succeeding day which shall not be such a day, by
presentation and surrender hereof to the Company at its principal office, or at the office of its
stock transfer agent, if any, with the subscription in the form of attached as Exhibit&nbsp;I
(&#147;Subscription&#148;) duly executed and accompanied by payment of the Exercise Price for the number of
Shares specified in such Subscription. If this Warrant should be exercised in part only, the
Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant
evidencing the rights of the Holder thereof to purchase the balance of the Shares purchasable
thereunder. Upon receipt by the Company of this Warrant at its office, or by the warrant agent of
the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder
of record of the Shares issuable upon such exercise, provided, however, that if at the date of
surrender of such Warrants and payment of such Exercise Price, the transfer books for the Shares
shall be closed, the certificates for the Shares, or other securities in respect of which such
Warrants are then exercised, shall be issuable as of the date on which such books shall next be
opened and until such date the Company shall be under no duty to deliver any certificate for such
Shares or such other securities and the Holder shall not be deemed to have become a holder of
record of such shares or the owner of any such other securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(B)&nbsp;RESERVATION OF SHARES. The Company hereby agrees that at all times there shall be reserved for
issuance and/or delivery upon exercise of this Warrant such number of Shares as shall be required
for issuance and delivery upon exercise of this Warrant. This Warrant is not redeemable by the
Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(C)&nbsp;FRACTIONAL SHARES. The Company shall not be required to issue fractions of Shares on the
exercise of Warrants. If any fraction of a Share would, except for the provisions of this Section,
be issuable on the exercise of any Warrant, the Company will: (1)&nbsp;if the fraction of a Share
otherwise issuable is equal to or less than one half, round down and issue to the Holder only the
largest whole number of Shares to which the Holder is otherwise entitled; or (2)&nbsp;if the fraction of
a Share otherwise issuable is greater than one-half, round-up and issue to the Holder one
additional Share in addition to the largest whole number of Shares to which the Holder is otherwise
entitled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(D)&nbsp;EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant is exchangeable, without
expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at
the office of its warrant agent, if any, for other Warrants of different denominations entitling
the Holder thereof to purchase in the aggregate the same number of Shares purchasable hereunder.
Subject to the provisions of Section (G), upon surrender of this Warrant to the Company or at the
office of its warrant agent, if any, with the assignment in the form attached as Exhibit&nbsp;II
(&#147;Assignment&#148;) duly executed and funds sufficient to pay any transfer tax, the Company shall,
without charge, execute and deliver a new Warrant in the name of the assignee named in such
instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided
or combined with other Warrants which carry the same rights upon presentation hereof at the office
of the Company or at the office of its warrant agent, if any, together with a written notice
specifying the names and denominations in which new Warrants are to be issued and signed by the
Holder hereof. The term &#147;Warrant&#148; as used herein includes any Warrants into which this Warrant may
be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss,
theft, destruction or mutilation of this Warrant, and (in
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the case of loss, theft or destruction) of such indemnification as the Company may in its
discretion impose, and upon surrender and cancellation of this Warrant, if mutilated, the Company
will execute and deliver a new Warrant of like tenor and date. Within thirty days following the
effective date of any registration statement pursuant to which the Warrants are registered, the
Company shall execute a warrant agreement and appoint a warrant agent, and such warrant agent
shall, upon presentment of the within warrant and at no expense to the Holder, reissue the Warrants
in traceable certificated form, substantially in the form hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(E)&nbsp;RIGHTS OF THE HOLDER. The Holder shall not be entitled, by virtue hereof, to any rights of a
shareholder in the Company, either at law or equity, and the rights of the Holder are limited to
those expressed in this Warrant and are not enforceable against the Company except to the extent
set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(F)&nbsp;ANTI-DILUTION PROVISIONS. The Exercise Price and the number and kind of securities purchasable
upon the exercise of this Warrant shall be subject to adjustment from time to time as hereinafter
provided:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(1)&nbsp;In case the Company shall issue Shares as a dividend upon Shares or in payment of a dividend
thereon, or shall subdivide the number of outstanding Shares into a greater number of shares or
shall contract the number of outstanding Shares into a lesser number of shares, the Exercise Price
then in effect shall be adjusted, effective at the close of business on the record date for the
determination of shareholders entitled to receive the same, to the price (computed to the nearest
cent) determined by dividing: (a)&nbsp;the product obtained by multiplying the Exercise Price in effect
immediately prior to the close of business on such record date by the number of
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares outstanding prior to such dividend, subdivision or contraction; by (b)&nbsp;the sum of the number
of Shares outstanding immediately after such dividend, subdivision, or contraction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(2)&nbsp;If any capital reorganization or reclassification of the capital stock of the Company, or
consolidation or merger of the Company with another corporation, or the sale of all or
substantially all of its assets to another corporation shall be effected, then, as a condition of
such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision
shall be made whereby the Holder of each Warrant shall thereafter have the right to purchase and
receive upon the basis and upon the terms and conditions specified in the Warrant and in lieu of
the Shares of the Company immediately theretofore purchasable and receivable upon the exercise of
the rights represented by such Warrant, such Shares, securities or assets as may be issued or
payable with respect to or in exchange for a number of outstanding Shares immediately theretofore
purchasable and receivable upon the exercise of the rights represented by such Warrant had such
reorganization, reclassification, consolidation, merger or sale not taken place, and in any such
case appropriate provision shall be made with respect to the rights and interest of the Holder to
the end that the provisions of the Warrant (including, without limitation, provisions for
adjustment of the Exercise Price and of the number of Shares issuable upon the exercise of
Warrants) shall thereafter be applicable as nearly as may be practicable in relation to any shares
of stock, securities, or assets thereafter deliverable upon exercise of Warrants. The Company shall
not effect any such consolidation, merger or sale unless prior to or simultaneously with the
consummation thereof, the successor corporation (if other than the Company) resulting from such
consolidation or merger or the corporation purchasing such assets shall assume, by written
instrument, the obligation to deliver to the Holder such shares of stock, securities or assets as,
in accordance with the foregoing provisions, the Holder may be entitled to purchase.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(3)&nbsp;Upon each adjustment of the Exercise Price pursuant to this Section (F), the number of shares
of Common Stock specified in each Warrant shall thereupon evidence the right to purchase that
number of shares of Common Stock (calculated to the nearest hundredth of a share of Common Stock)
obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the
number of shares of Common Stock purchasable immediately by the Exercise Price in effect after such
adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(4)&nbsp;Irrespective of any adjustment of the number or kind of securities issuable upon exercise of
Warrants or the Exercise Price, Warrants theretofore or thereafter issued may continue to express
the same number of Shares and Exercise Price as are stated in similar Warrants previously issued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(5)&nbsp;The Company may, at its sole option, retain the independent public accounting firm regularly
retained by the Company, or another firm of independent public accountants of recognized standing
selected by the Company&#146;s Board of Directors, to make any computation required under this Section
(F)&nbsp;and a certificate signed by such firm shall be conclusive evidence of any computation made
under this Section (F).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(6)&nbsp;Whenever there is an adjustment in the Exercise Price or in the number or kind of securities
issuable upon exercise of the Warrants, or both, as provided in this Section (F), the Company
shall: (i)&nbsp;promptly file in the custody of its Secretary or Assistant Secretary a certificate
signed by the Chairman of the Board or the President or a Vice President of the Company and by the
Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary of the Company,
showing in detail the facts requiring such adjustment and the number and kind of securities
issuable upon exercise of each Warrant after such adjustment; and (ii)&nbsp;cause a notice stating that
such adjustment has been effected and stating the Exercise Price then
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in effect and the number and kind of securities issuable upon exercise of each Warrant to be sent
to each registered holder of Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(7)&nbsp;In addition to the adjustments otherwise set forth in this Section (F), the Company, in its
sole discretion, may reduce the Exercise Price or extend the expiration date of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(8)&nbsp;The Exercise Price and the number of Shares issuable upon exercise of a Warrant shall be
adjusted in the manner and only upon the occurrence of the events heretofore specifically referred
to in this Section (F).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(G)&nbsp;TRANSFER TO COMPLY WITH THE 1933 ACT AND OTHER APPLICABLE SECURITIES LAWS. This Warrant or the
Shares issuable upon exercise of this Warrant, or any other security issued or issuable upon
exercise of this Warrant, may not be transferred, assigned, pledged, sold or otherwise disposed of
unless Holder provides the Company with an opinion of counsel satisfactory to the Company in form
satisfactory to the Company (together with such other representations and warranties as the Company
may request) that this Warrant or the Shares issued or issuable upon exercise of this Warrant may
be legally transferred without violating the 1933 Act and any other applicable securities law and
then only against receipt of an agreement of the transferee (in form and substance satisfactory to
the Company) to comply with the provisions of this Section (G)&nbsp;with respect to any resale or other
disposition of such securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(H)&nbsp;SURVIVAL. All agreements, covenants, representations and warranties herein shall survive the
execution and delivery of this Warrant and any investigation at any time made by or on behalf of
any parties hereto and the exercise and purchase of this Warrant.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(I)&nbsp;AMENDMENTS; WAIVERS; TERMINATIONS; GOVERNING LAW; HEADINGS. This Warrant and any terms
hereof may be changed, waived, discharged or terminated only by an instrument in writing signed by
the party against which enforcement of such change, waiver, discharge or termination is sought.
This Warrant shall be governed by and construed and interpreted in accordance with the laws of the
State of Georgia. The headings in this Warrant are for convenience of reference only and are not
part of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(J)&nbsp;REGISTRATION RIGHTS. The undersigned Holder shall have piggyback registration rights as set
forth in paragraph B 12 of that certain Subscription Agreement by and between the Company and the
undersigned Holder dated August&nbsp;6, 2007.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be signed in its name and on its
behalf and its corporate seal to be affixed hereon by its duly authorized officers.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>GEOVAX LABS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 6pt"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attest:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">EXHIBIT I

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Subscription Form</U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(To be executed only upon exercise of Warrant)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registered owner of this Warrant irrevocably exercises this Warrant for and
purchases <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares of GeoVax Labs, Inc., purchasable with this Warrant, and herewith
makes payment therefor, all at the price and on the terms and conditions specified in this Warrant
and requests that certificates for the Shares hereby purchased (and any securities or other
property issuable upon such exercise) be issued in the name of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and delivered to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>whose address is <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and, if such Shares shall not include all of the Shares issuable as provided in this
Warrant, that a new Warrant of like tenor and date for the balance of the Shares issuable
thereunder to be delivered to the undersigned.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Name)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Street Address)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">(City)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (State)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">EXHIBIT II

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Assignment Form</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR VALUE RECEIVED the undersigned registered owner of this Warrant hereby sells, assigns and
transfers unto the assignee named below all of the rights of the undersigned under this Warrant,
with respect to the number of Shares set forth below;
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 6pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD align="left" valign="top"><U>Name and Address of Assignee</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">No. of Shares: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and does hereby irrevocably constitute and appoint <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, as attorney, to resister such transfer on the books of GeoVax Labs, Inc.,
maintained for the purpose, with full power of substitution in the premises.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Witness:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notice: The signature to this assignment must correspond with the name as written upon the
face of the within Warrant in every particular, without alteration or enlargement or any change
whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The signature to this assignment must be guaranteed by a bank or trust company
having an office or correspondent in New York, New York, or by a firm having membership on the New
York Stock Exchange.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><U><B>EXHIBIT B</B></U>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FORM OF NOVEMBER 5, 2007 WARRANT</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">THIS WARRANT AND THE SECURITIES UNDERLYING THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE &#147;1933 ACT&#148;), OR UNDER APPLICABLE STATE SECURITIES LAWS. THE
WARRANT HAS BEEN TAKEN BY THE REGISTERED OWNER FOR INVESTMENT, AND WITHOUT A VIEW TO RESALE OR
DISTRIBUTION THEREOF, AND MAY NOT BE TRANSFERRED OR DISPOSED OF WITHOUT AN OPINION OF COUNSEL
SATISFACTORY TO THE ISSUER THAT SUCH TRANSFER OR DISPOSITION DOES NOT VIOLATE THE 1933 ACT, THE
RULES AND REGULATIONS THEREUNDER, OR APPLICABLE STATE SECURITIES LAWS. IN CONNECTION WITH
COMPLIANCE WITH THE 1933 ACT AND APPLICABLE STATE SECURITIES LAWS, NO TRANSFER OF THIS WARRANT OR
THE SECURITIES UNDERLYING THIS WARRANT SHALL BE MADE UNLESS THE CONDITIONS SPECIFIED HEREIN ARE
SATISFIED.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><B>No. &#95;&#95;&#95;</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top"><B>Shares: 16,666,667</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>GEOVAX LABS, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>COMMON STOCK PURCHASE WARRANT</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This is to certify that, for value received, PURE Capital, LLC (&#147;Holder&#148;) is entitled to
purchase, subject to the provisions of this Common Stock Purchase Warrant (&#147;Warrant&#148;), from GEOVAX
LABS, INC., a corporation duly organized and existing under the laws of the State of Illinois (the
&#147;Company&#148;), 16,666,667 shares of $0.001 par value per share common stock of the Company (&#147;Shares&#148;),
at a price of U.S. $&#95;&#95;&#95;&#091;insert an amount equal to the closing market price on November&nbsp;2, 2007&#093;
per Share, during the period commencing November&nbsp;5, 2007, and terminating on November&nbsp;4, 2010, at
5:00 P.M. New York Time. This Warrant is not redeemable by the Company. The number of Shares to be
received upon the exercise of this Warrant and the price to be paid for a Share may be adjusted
from time to time as hereinafter set forth. The exercise price of a Share in effect at any time and
as adjusted from time to time is hereinafter sometimes referred to as &#147;Exercise Price.&#148;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(A)&nbsp;EXERCISE OF WARRANT. Subject to the provisions of Section (G)&nbsp;hereof, this Warrant may be
exercised in whole or in part at any time or from time to time on or after November&nbsp;5, 2007 and
until November&nbsp;4, 2010, or, if either such day is a day on which banking institutions are
authorized by law to close, then on the next succeeding day which shall not be such a day, by
presentation and surrender hereof to the Company at its principal office, or at the office of its
stock transfer agent, if any, with the subscription in the form of attached as Exhibit&nbsp;I
(&#147;Subscription&#148;) duly executed and accompanied by payment of the Exercise Price for the number of
Shares specified in such Subscription. If this Warrant should be exercised in part only, the
Company shall, upon surrender of this Warrant for cancellation, execute and deliver a new Warrant
evidencing the rights of the Holder thereof to purchase the balance of the Shares purchasable
thereunder. Upon receipt by the Company of this Warrant at its office, or by the warrant agent of
the Company at its office, in proper form for exercise, the Holder shall be deemed to be the holder
of record of the Shares issuable upon such exercise, provided, however, that if at the date of
surrender of such Warrants and payment of such Exercise Price, the transfer books for the Shares
shall be closed, the certificates for the Shares, or other securities in respect of which such
Warrants are then exercised, shall be issuable as of the date on which such books shall next be
opened and until such date the Company shall be under no duty to deliver any certificate for such
Shares or such other securities and the Holder shall not be deemed to have become a holder of
record of such shares or the owner of any such other securities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(B)&nbsp;RESERVATION OF SHARES. The Company hereby agrees that at all times there shall be reserved for
issuance and/or delivery upon exercise of this Warrant such number of Shares as shall be required
for issuance and delivery upon exercise of this Warrant. This Warrant is not redeemable by the
Company.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(C)&nbsp;FRACTIONAL SHARES. The Company shall not be required to issue fractions of Shares on the
exercise of Warrants. If any fraction of a Share would, except for the provisions of this Section,
be issuable on the exercise of any Warrant, the Company will: (1)&nbsp;if the fraction of a Share
otherwise issuable is equal to or less than one half, round down and issue to the Holder only the
largest whole number of Shares to which the Holder is otherwise entitled; or (2)&nbsp;if the fraction of
a Share otherwise issuable is greater than one-half, round-up and issue to the Holder one
additional Share in addition to the largest whole number of Shares to which the Holder is otherwise
entitled.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(D)&nbsp;EXCHANGE, TRANSFER, ASSIGNMENT OR LOSS OF WARRANT. This Warrant is exchangeable, without
expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at
the office of its warrant agent, if any, for other Warrants of different denominations entitling
the Holder thereof to purchase in the aggregate the same number of Shares purchasable hereunder.
Subject to the provisions of Section (G), upon surrender of this Warrant to the Company or at the
office of its warrant agent, if any, with the assignment in the form attached as Exhibit&nbsp;II
(&#147;Assignment&#148;) duly executed and funds sufficient to pay any transfer tax, the Company shall,
without charge, execute and deliver a new Warrant in the name of the assignee named in such
instrument of assignment and this Warrant shall promptly be canceled. This Warrant may be divided
or combined with other Warrants which carry the same rights upon presentation hereof at the office
of the Company or at the office of its warrant agent, if any, together with a written notice
specifying the names and denominations in which new Warrants are to be issued and signed by the
Holder hereof. The term &#147;Warrant&#148; as used herein includes any Warrants into which this Warrant may
be divided or exchanged. Upon receipt by the Company
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Warrant, and
(in the case of loss, theft or destruction) of such indemnification as the Company may in its
discretion impose, and upon surrender and cancellation of this Warrant, if mutilated, the Company
will execute and deliver a new Warrant of like tenor and date. Within thirty days following the
effective date of any registration statement pursuant to which the Warrants are registered, the
Company shall execute a warrant agreement and appoint a warrant agent, and such warrant agent
shall, upon presentment of the within warrant and at no expense to the Holder, reissue the Warrants
in traceable certificated form, substantially in the form hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(E)&nbsp;RIGHTS OF THE HOLDER. The Holder shall not be entitled, by virtue hereof, to any rights of a
shareholder in the Company, either at law or equity, and the rights of the Holder are limited to
those expressed in this Warrant and are not enforceable against the Company except to the extent
set forth herein.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(F)&nbsp;ANTI-DILUTION PROVISIONS. The Exercise Price and the number and kind of securities purchasable
upon the exercise of this Warrant shall be subject to adjustment from time to time as hereinafter
provided:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(1)&nbsp;In case the Company shall issue Shares as a dividend upon Shares or in payment of a dividend
thereon, or shall subdivide the number of outstanding Shares into a greater number of shares or
shall contract the number of outstanding Shares into a lesser number of shares, the Exercise Price
then in effect shall be adjusted, effective at the close of business on the record date for the
determination of shareholders entitled to receive the same, to the price (computed to the nearest
cent) determined by dividing: (a)&nbsp;the product obtained by multiplying the Exercise
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Price in effect immediately prior to the close of business on such record date by the number of
Shares outstanding prior to such dividend, subdivision or contraction; by (b)&nbsp;the sum of the number
of Shares outstanding immediately after such dividend, subdivision, or contraction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(2)&nbsp;If any capital reorganization or reclassification of the capital stock of the Company, or
consolidation or merger of the Company with another corporation, or the sale of all or
substantially all of its assets to another corporation shall be effected, then, as a condition of
such reorganization, reclassification, consolidation, merger or sale, lawful and adequate provision
shall be made whereby the Holder of each Warrant shall thereafter have the right to purchase and
receive upon the basis and upon the terms and conditions specified in the Warrant and in lieu of
the Shares of the Company immediately theretofore purchasable and receivable upon the exercise of
the rights represented by such Warrant, such Shares, securities or assets as may be issued or
payable with respect to or in exchange for a number of outstanding Shares immediately theretofore
purchasable and receivable upon the exercise of the rights represented by such Warrant had such
reorganization, reclassification, consolidation, merger or sale not taken place, and in any such
case appropriate provision shall be made with respect to the rights and interest of the Holder to
the end that the provisions of the Warrant (including, without limitation, provisions for
adjustment of the Exercise Price and of the number of Shares issuable upon the exercise of
Warrants) shall thereafter be applicable as nearly as may be practicable in relation to any shares
of stock, securities, or assets thereafter deliverable upon exercise of Warrants. The Company shall
not effect any such consolidation, merger or sale unless prior to or simultaneously with the
consummation thereof, the successor corporation (if other than the Company) resulting from such
consolidation or merger or the corporation purchasing such assets shall assume, by written
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">instrument, the obligation to deliver to the Holder such shares of stock, securities or assets as,
in accordance with the foregoing provisions, the Holder may be entitled to purchase.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(3)&nbsp;Upon each adjustment of the Exercise Price pursuant to this Section (F), the number of shares
of Common Stock specified in each Warrant shall thereupon evidence the right to purchase that
number of shares of Common Stock (calculated to the nearest hundredth of a share of Common Stock)
obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the
number of shares of Common Stock purchasable immediately by the Exercise Price in effect after such
adjustment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(4)&nbsp;Irrespective of any adjustment of the number or kind of securities issuable upon exercise of
Warrants or the Exercise Price, Warrants theretofore or thereafter issued may continue to express
the same number of Shares and Exercise Price as are stated in similar Warrants previously issued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(5)&nbsp;The Company may, at its sole option, retain the independent public accounting firm regularly
retained by the Company, or another firm of independent public accountants of recognized standing
selected by the Company&#146;s Board of Directors, to make any computation required under this Section
(F)&nbsp;and a certificate signed by such firm shall be conclusive evidence of any computation made
under this Section (F).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(6)&nbsp;Whenever there is an adjustment in the Exercise Price or in the number or kind of securities
issuable upon exercise of the Warrants, or both, as provided in this Section (F), the Company
shall: (i)&nbsp;promptly file in the custody of its Secretary or Assistant Secretary a certificate
signed by the Chairman of the Board or the President or a Vice President of the Company and by the
Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary of the Company,
showing in detail the facts requiring such adjustment and the number
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and kind of securities issuable upon exercise of each Warrant after such adjustment; and (ii)&nbsp;cause
a notice stating that such adjustment has been effected and stating the Exercise Price then in
effect and the number and kind of securities issuable upon exercise of each Warrant to be sent to
each registered holder of Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(7)&nbsp;In addition to the adjustments otherwise set forth in this Section (F), the Company, in its
sole discretion, may reduce the Exercise Price or extend the expiration date of the Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(8)&nbsp;The Exercise Price and the number of Shares issuable upon exercise of a Warrant shall be
adjusted in the manner and only upon the occurrence of the events heretofore specifically referred
to in this Section (F).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(G)&nbsp;TRANSFER TO COMPLY WITH THE 1933 ACT AND OTHER APPLICABLE SECURITIES LAWS. This Warrant or the
Shares issuable upon exercise of this Warrant, or any other security issued or issuable upon
exercise of this Warrant, may not be transferred, assigned, pledged, sold or otherwise disposed of
unless Holder provides the Company with an opinion of counsel satisfactory to the Company in form
satisfactory to the Company (together with such other representations and warranties as the Company
may request) that this Warrant or the Shares issued or issuable upon exercise of this Warrant may
be legally transferred without violating the 1933 Act and any other applicable securities law and
then only against receipt of an agreement of the transferee (in form and substance satisfactory to
the Company) to comply with the provisions of this Section (G)&nbsp;with respect to any resale or other
disposition of such securities.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(H)&nbsp;SURVIVAL. All agreements, covenants, representations and warranties herein shall survive the
execution and delivery of this Warrant and any investigation at any time made by or on behalf of
any parties hereto and the exercise and purchase of this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(I)&nbsp;AMENDMENTS; WAIVERS; TERMINATIONS; GOVERNING LAW; HEADINGS. This Warrant and any terms hereof
may be changed, waived, discharged or terminated only by an instrument in writing signed by the
party against which enforcement of such change, waiver, discharge or termination is sought. This
Warrant shall be governed by and construed and interpreted in accordance with the laws of the State
of Georgia. The headings in this Warrant are for convenience of reference only and are not part of
this Warrant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(J)&nbsp;REGISTRATION RIGHTS. The undersigned Holder shall have piggyback registration rights as set
forth in paragraph B 12 of that certain Subscription Agreement by and between the Company and the
undersigned Holder dated August&nbsp;6, 2007.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>IN WITNESS WHEREOF</B>, the Company has caused this Warrant to be signed in its name and on its
behalf and its corporate seal to be affixed hereon by its duly authorized officers.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left"><B>GEOVAX LABS, INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"  style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 6pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Attest:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">EXHIBIT I

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Subscription Form</U>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">(To be executed only upon exercise of Warrant)

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned registered owner of this Warrant irrevocably exercises this Warrant for and
purchases <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> Shares of GeoVax Labs, Inc., purchasable with this Warrant, and herewith
makes payment therefor, all at the price and on the terms and conditions specified in this Warrant
and requests that certificates for the Shares hereby purchased (and any securities or other
property issuable upon such exercise) be issued in the name of
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> and delivered to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> whose address is<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
and, if such Shares shall not include all of the Shares issuable as provided in this
Warrant, that a new Warrant of like tenor and date for the balance of the Shares issuable
thereunder to be delivered to the undersigned.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Name)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Street Address)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD colspan="3" valign="top" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" nowrap valign="top">(City)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (State)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Zip Code)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">EXHIBIT II

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>Assignment Form</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR VALUE RECEIVED the undersigned registered owner of this Warrant hereby sells, assigns and
transfers unto the assignee named below all of the rights of the undersigned under this Warrant,
with respect to the number of Shares set forth below;
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%"></TD>
    <TD width="5%"></TD>
    <TD width="47%"></TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><U>Name and Address of Assignee</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">No. of Shares: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and does hereby irrevocably constitute and appoint <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>, as attorney, to resister such transfer on the books of GeoVax Labs, Inc.,
maintained for the purpose, with full power of substitution in the premises.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Signature:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR><TR style="font-size: 6pt"><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Witness:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notice: The signature to this assignment must correspond with the name as written upon the face of
the within Warrant in every particular, without alteration or enlargement or any change whatsoever.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">The signature to this assignment must be guaranteed by a bank or trust company
having an office or correspondent in New York, New York, or by a firm having membership on the New
York Stock Exchange.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>g08657exv99w1.htm
<DESCRIPTION>EX-99.1 PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1 PRESS RELEASE</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>AT THE COMPANY</U><BR>
Donald Hildebrand / Jennifer Nelms<BR>
(404)&nbsp;727-0971

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FOR IMMEDIATE RELEASE<BR>
31 JULY 2007

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX SIGNS A $7.5 MILLION PRIVATE PLACEMENT AGREEMENT<BR>
Investment Supports GeoVax AIDS Vaccine Development</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ATLANTA, Ga., 31 July&nbsp;2007 &#150; GeoVax Labs, Inc. (OTC:BB GOVX), an Atlanta-based biotechnology
company developing human AIDS vaccines, today announced that it has entered into a definitive
agreement with PURE Capital LLC, a newly formed investment subsidiary of an established private
investment firm, for the sale of $7.5&nbsp;million of GeoVax common stock. Under the terms of the
financing, the investment will be made in two closings to occur on August 6 and on November 5. The
investor will also receive warrants to purchase additional shares of GeoVax common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Don Hildebrand, GeoVax CEO, President and CEO, stated, &#147;We are exceptionally pleased with the
positive response to our progress at GeoVax as reflected by this financing. This major investment
by an institutional investor greatly enhances our AIDS vaccine development and human trials
program. The $7.5&nbsp;million funding allows us to push forward into larger scale Phase 2 human
clinical trials (AIDS prevention), involving substantially more human participants, and the
potential commencement of our therapeutic (AIDS treatment) clinical trials currently under
consideration.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Summary of Private Placement Terms are as follows:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>First Closing &#150; $3.5&nbsp;million (22,580,645 shares) scheduled for closing on August&nbsp;6, 2007.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Second Closing &#150; $4.0&nbsp;million (25,806,452 shares) scheduled for closing on November&nbsp;5,
2007.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the time of the First Closing, the investor will receive a warrant (First Warrant) to
purchase an additional 18,333,333 shares of GeoVax common stock at an exercise price of
$0.33 per share and a 3&nbsp;year exercise period. Provided the investor exercises his right to
convert the First Warrant into GeoVax common shares within the 3&nbsp;year exercise period, an
additional $6,050,000 shall be paid to GeoVax.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>At the time of the Second Closing, the investor will receive a warrant (Second Warrant)
to purchase an additional 16,666,667 shares of GeoVax common stock at an exercise price
equal to the closing market price on the day immediately preceding the Second Closing.
Therefore, additional proceeds to GeoVax arising from the investor&#146;s potential exercise of
the Second Warrant can not be determined at this time.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax granted the investor only &#147;piggyback&#148; registration rights as to all the shares
subject to the agreement (including shares underlying the warrants). Therefore, all shares
to be issued under the agreement will be subject to SEC Rule&nbsp;144 holding period
requirements, resulting in a one year restriction from trading from the date the shares are
acquired by the investor. Should GeoVax file a registration statement in an underwritten
public offering, the investor may require GeoVax to include their shares in the
registration (subject to certain conditions).</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We have selected this particular investment package over other potential opportunities presented
to us because of the more favorable terms associated with this transaction, including but not
limited to registration requirements beneficial to GeoVax and protection of the integrity of
previous investments in the company,&#148; further commented Don Hildebrand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition to the Phase 2 trials being planned for 2008, GeoVax currently has four (4)&nbsp;human
trials underway. As recently announced, early positive immune responses from the first two (2)
trials allowed the accelerated start of human trials number 3 and 4 in June&nbsp;2007. These trials
began more than a month earlier than originally anticipated. &#147;Success in these trials could lead to
a simpler vaccine regime making it easier to vaccinate people,&#148; stated Dr.&nbsp;Harriet Robinson, Ph.D.,
GeoVax Scientific Advisory Board Chairperson.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">****************************************

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About GeoVax Labs, Inc. (www.geovax.com)</B>

</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Inc., based in Atlanta, Georgia USA, is a biotechnology company, established to develop,
license and commercialize the manufacture and sale of human vaccines for diseases caused by HIV-1
&#091;Human Immunodeficiency Virus&#093; and other infectious agents.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax&#146;s HIV/AIDS vaccines protected 22/23 (96%) non-human primates for over 3<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> years
post-infection with an AIDS causing virus &#150; 5 of 6 non-vaccinates controls died of AIDS</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax&#146;s HIV/AIDS vaccines have been satisfactorily manufactured and tested under
GMP/GLP &#150; EMEA (EU) &#038; FDA guidelines</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax&#146;s AIDS-DNA vaccine satisfactory completed Phase I human clinical trials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax&#146;s HIV/AIDS vaccines are currently in four ongoing human trials</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Results from the first two trials indicate positive immune responses reported in the
majority of vaccine recipients as well as good vaccine safety profile.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Phase 2 Human Trial is planned for early 2008.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GeoVax&#146;s HIV/AIDS vaccine technology is protected by 20 issued and filed patent
applications</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Safe Harbor Statement: All statements in this news release that are not statements of
historical fact are forward-looking statements. These statements are based on expectations and
assumptions as of the date of this press release and are subject to numerous risks and
uncertainties which could cause actual results to differ materially from those described in the
forward-looking statements. Risks and uncertainties include, but are not limited to, whether;
GeoVax can develop these vaccines with the desired characteristics in a timely manner, GeoVax&#146;s
vaccines will be determined to be safe for use in humans, GeoVax&#146;s vaccines will be effective in
preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be
licensed and marketed, GeoVax can raise the required capital to complete development of its
vaccines, there is development of competitive products that may be more effective or easier to use
than GeoVax&#146;s products, and other factors over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does not intend to do so. Certain
matters discussed in this news release are forward looking statements involving certain risks and
uncertainties including, without limitations, risks detailed in the Companies Securities and
Exchange Commission filings and reports.</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
